XTX Topco Ltd Purchases 6,890 Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT)

XTX Topco Ltd raised its position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 53.0% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 19,900 shares of the company’s stock after purchasing an additional 6,890 shares during the quarter. XTX Topco Ltd owned 0.07% of ClearPoint Neuro worth $223,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Verition Fund Management LLC bought a new stake in shares of ClearPoint Neuro during the third quarter valued at approximately $123,000. Pekin Hardy Strauss Inc. purchased a new stake in ClearPoint Neuro during the 3rd quarter valued at $541,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of ClearPoint Neuro in the 3rd quarter worth $366,000. Oppenheimer & Co. Inc. purchased a new position in shares of ClearPoint Neuro in the third quarter worth $156,000. Finally, Essex Investment Management Co. LLC lifted its holdings in shares of ClearPoint Neuro by 0.3% during the third quarter. Essex Investment Management Co. LLC now owns 463,853 shares of the company’s stock valued at $5,200,000 after purchasing an additional 1,267 shares in the last quarter. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Trading Down 2.8 %

Shares of CLPT opened at $14.66 on Friday. The firm has a fifty day simple moving average of $12.84 and a two-hundred day simple moving average of $10.24. The firm has a market cap of $404.40 million, a PE ratio of -21.25 and a beta of 1.08. ClearPoint Neuro, Inc. has a 1-year low of $5.11 and a 1-year high of $17.47.

Analysts Set New Price Targets

Separately, Lake Street Capital lifted their price objective on ClearPoint Neuro from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.